Treatment of platelets with GPIIbIIIa antagonists, thrombin and A23187, and determination of caspase-3 activation
In order to mimic an in vivo situation, in this study, we used platelet-rich plasma (PRP), rather than washed platelets, to investigate the effect of Integrilin and Aggrastat on caspase-3 activation in the presence of plasma proteins.
Venous blood from healthy volunteers was anticoagulated with 0.32% sodium citrate and PRP was obtained by centrifugation at 180 g for 15 min at room temperature (RT). Caspase-3 activation was determined as previously described 1,2 using the cell-penetrating carboxyfluorescein-labeled FAM-DEVD-FMK probe, which covalently binds to active caspase-3.
3 To study the effect of Integrilin and Aggrastat on caspase-3 activation in resting platelets, GPIIbIIIa antagonists at final concentrations of 0.48-4.8 µM or control diluent buffer A were incubated with citrated PRP for 45 min at RT. In platelets stimulated with thrombin or A23187, GPIIbIIIa antagonists at final concentration of 0.48 µM or buffer A were preincubated with PRP for 30 min at RT followed by incubation for 15 min at RT with either 1 U/mL human-α thrombin plus 2.5 mM GPRP or 10 µM A23187 (final concentrations).
For detecting caspase-3 activation, 5 µL aliquots of 10X working FAM-DEVD-FMK solution, prepared according to the manufacturer's recommendations, were added to 45 µL of treated platelet samples and incubated for 60 min at 37°C in the dark. Following dilution to 500 µL with buffer A, samples were acquired within 30-60 min, fluorescent (FL1) histograms were analyzed, and caspase-3 activation was quantified as the mean channel fluorescence (MCF) of platelet-bound FAM-DEVD-FMK.
Calculation of inhibitory effect of GPIIbIIIa antagonists on caspase-3 activation
To quantify the impact of Integrilin and Aggrastat on caspase-3 activation in platelets stimulated with thrombin and A23187, the percentage of inhibition of caspase-3 activation was calculated in each experiment by the formula:
Inhibition, % = (AG -AN) x 100% / (AG -CON), where AG: caspase-3 activation in platelets treated with platelet agonist (thrombin or A23187), AN: caspase-3 activation in platelets treated with GPIIbIIIa antagonist (Integrilin or Aggrastat) plus platelet agonist, and CON: caspase-3 activation in platelets treated with control diluent buffer A.
Statistical analysis
Data of seven experiments are presented as means ± SEM. The statistical significance of the differences between different platelet groups was determined by one-way ANOVA with Dunnett's multiple comparison post hoc test. Differences were considered significant when p<0.05. 
